OncoGeneX Technologies Inc.
This article was originally published in Start Up
Executive Summary
OncoGeneX Technologies was founded specifically to develop OGX-011, a compound that inhibits the production of clusterin, a cell survival protein found to be up-regulated in many cancers after exposure to standard cancer therapies including chemotherapy, radiation therapy, and hormone ablation.
You may also be interested in...
PhageTech Inc.
PhageTech is mining the genome of phage virus, which infect bacteria, for targets with which to create a new generation of antibiotics.
Thios Pharmaceuticals Inc.
Sulfation is the process in which sulfate recovered by cells from the bloodstream is attached to target molecules, such as glycoproteins. Thios Pharmaceuticals, formed around its founders' sulfation research, believes these pathways will be fertile ground for identifying a new class of therapeutic targets.
Cyclis Pharmaceuticals Inc.
Normally during the cell cycle, molecular signaling checkpoints prevent cell division in the event of chromosomal shuffling or DNA damage. Cyclis Pharmaceuticals is developing cancer drugs that turn on the deactivated cellular surveillance system, leading to apoptosis and cell death.